Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results

 Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results

PR Newswire

ATLANTA, May 3, 2013

ATLANTA, May 3, 2013 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that it will release its first quarter fiscal year 2013
financial results after the market close on Thursday, May 9, 2013. An investor
conference call will follow on the same day at 4:30 p.m. ET.

The conference call will be hosted by Dan Myers, President and Chief Executive
Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial
Officer.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or
(253) 237-1165 (international). A live webcast will be available on the
Investor Relations section of the corporate website at
http://www.alimerasciences.com.

A replay of the conference call will be available beginning May 9, 2013 at
7:30 p.m. ET and ending on May 15, 2013 by dialing (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international), Conference ID Number: 64145879. A
replay of the webcast will be available on the corporate website for one week,
through May 15, 2013.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a
non-proprietary corticosteroid with demonstrated efficacy in the treatment of
ocular disease.

Investor Contact:
ICR, LLC
John Mills
310-954-1105
John.Mills@icrinc.com

SOURCE Alimera Sciences, Inc.

Website: http://www.alimerasciences.com